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Abstract 
Background: Mineralocorticoid Receptor Antagonists (MRAs) are recommended (unless 
contraindicated) to all patients with heart failure with reduced ejection fraction (HFrEF). 
However, MRAs are still largely underused in routine clinical practice.  
Aims: This study aims to describe the determinants and pattern of use of MRAs in HFrEF.  
Methods: BIOSTAT-CHF i s  an  European  multicentre, prospective study which 
enrolled patients sub-optimally treated with ACE-inhibitors/ARBs and/or β-blockers, with 
the aim of optimizing guideline based use of these agents. From the original 2516 
subjects, this retrospective post hoc analysis included the 1325 patients with an indication 
for MRA therapy (i.e., LVEF≤35%, eGFR≥30 ml/min/1.73m2, K+≤5.0 mmol/L).  
Results: The mean age was 66.1±12.2 years. At baseline an MRA was prescribed 741 (56%) 
patients. Patients who were prescribed MRAs at baseline were younger, more often male, had 
higher BMI, lower sodium, higher proportion of hypertension history and ACEi/ARBs 
prescription (all p<0.05). Of the 1049 patients who completed the baseline plus the 9-month 
visit, 585 (56%) had an MRA prescribed at baseline and 662 (63%) patients had an MRA 
prescribed at 9-months. Among the 585 patients with MRA at baseline, 91 (16%) had 
discontinued therapy and among the 461 (44%) patients without MRA at baseline 168 (36%) 
had initiated therapy subsequently. MRA discontinuation was more likely in subjects with 
higher LVEF and NYHA class III/IV (p<0.05 for both). MRA prescription both at baseline and 
9 months was not associated with the outcome of death or HF hospitalization (adjusted HR 
[95%CI]=1.02 [0.66-1.58], p=0.93). 
Conclusions: In this prospective observational study across Europe, MRAs were largely under-
prescribed and frequently discontinued. Due to these dynamic changes outcome inferences are 
inconclusive. 
 
Key-words: Mineralocorticoid receptor antagonists; real-life; observational, adherence, 
prescription. 
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Introduction 
Mineralocorticoid receptor antagonists (MRAs) improve morbidity and reduce mortality 
in heart failure with reduced ejection fraction (HFrEF) with severe symptoms (spironolactone)1, 
mild symptoms (eplerenone)2, and in post-myocardial infarction with systolic dysfunction 
and/or heart failure (eplerenone)3. Mortality rates were reduced by 15% to 30% and heart failure 
(HF) readmissions dropped up to 40% in these landmark trials. 
Despite these remarkable improvements in morbidity and mortality and a class IA 
guideline recommendations, MRAs are still largely underused in routine clinical practice4, 5. 
This may be (at least partly) explained by an undue concern about inducing hyperkalemia or 
worsening renal function6-14 and the need of close monitoring of potassium and renal function7, 
but also by a lack of education/promotion about these drugs and their indications8-14. 
 “Real-life” data suggest that non-compliance and discontinuation of therapy is 
common, especially with regards to MRAs, with less than 50% of daily doses ingested in some 
series (i.e., a much lower adherence than that reported for angiotensin converting enzyme 
inhibitors/angiotensin receptor blockers [ACEi/ARBs] and β-blockers, for example)15, 16. Many 
reports of “real-life” observational data pointed to a lack of association of MRA therapy with 
clinical benefit, in contrast with the findings of multiple randomised clinical trials.  No matter 
how extensive are adjustment in statistical analyses, such observation data are usually fraught 
with residual bias17, 18. We hypothesize that one of the major and often overlooked biases is the 
wrong assumption that patients prescribed MRA therapy at baseline keep their medications 
unchanged throughout the course of the observation period. Hence, the main goals of the 
present analysis are to study: 1) the rates and determinants of MRA prescription; 2) the 
characteristics of the population with and without MRAs prescribed; 3) the changes in MRA 
therapy that occurs after baseline observation and during the 9-month period after the baseline 
observation, and 4) the determinants of these changes. We took advantage of the European 
BIOSTAT-CHF program as a multicentre, multinational, prospective, contemporary, 
observational study which enrolled patients who had suboptimal dosing or no treatment with 
ACE-inhibitors/ARBs and/or β-blockers, with the aim of optimizing guideline based use of 
these agents and examining the predictors of optimization. Patients’ characteristics are 
compared at baseline (visit 1) and 9 months (visit 2) follow up. This retrospective post hoc 
analysis was restricted to patients indicated for MRA therapy. 
 
Methods 
Patient population 
BIOSTAT-CHF is a European project that enrolled 2516 HF patients from 69 centres 
in 11 European countries to determine profiles of patients with HF that do not respond to 
recommended therapies, despite anticipated up-titration. The design of the study and patients 
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have been described elsewhere19. In brief, patients were aged ≥18 years with symptoms of new-
onset or worsening HF, confirmed either by a left ventricular ejection fraction (LVEF) of ≤40% 
or a BNP and/or NT-proBNP plasma levels >400 pg/ml or >2000pg/ml, respectively. Patients 
needed to be treated with either oral or intravenous furosemide ≥40 mg/day or equivalent at the 
time of inclusion. Patients should not have been previously treated with evidence based 
therapies (ACEi/ARBs and β-blockers) or were receiving <50% of the target doses of at least 
one of these drugs at the time of inclusion. Initiation or up-titration of ACEi/ARB and/or β-
blocker therapy should have been anticipated by the treating physician. The first three months of 
treatment were considered to be the optimization phase after which a stabilization phase of 6 
months was defined. During the optimization phase, initiation or up-titration of ACEi/ARB 
and/or β-blocker was performed according to the routine clinical practice of the treating 
physicians, who were encouraged to follow the ESC guidelines at the time of treatment20, 21. 
There were no inclusion criteria nor optimization strategy specific to MRA therapy, which is 
assumed to be reflective of “usual care”. 
The recruitment period was 24 months, starting from December 2010. The last patient 
was included on December 15, 2012. Median follow-up was 21 months.  
From the original 2516 patients enrolled in the BIOSTAT-CHF program, the 
retrospective analysis only included 1325 patients with a formal indication for the use of an 
MRA (LVEF ≤35%, estimated glomerular filtration rate [eGFR] ≥30 ml/min/1.73m2, and 
K+ ≤5.0 mmol/L) – Figure 1.  
Statistical analysis 
In descriptive analyses, continuous variables are expressed as mean ± standard deviation 
(SD). Categorical variables are expressed as frequencies and proportions (%). Population 
description and comparison of patients with MRA vs. without MRA prescribed was performed 
using independent samples t-test for normally distributed continuous variables and chi-square 
test for categorical variables. Normality assumptions were verified by visual binning. No 
multiple imputation was performed.  
To determine predictors of having a MRA prescribed (or not) and discontinued (or not), 
we developed two logistic regression and two multinomial prediction models. Both models used 
clinical and laboratory variables with a p-value <0.2 as entry criteria. The first model was a 
forward conditional model eliminating progressively the variables with weaker association and 
retaining in the final model those variables with a p <0.05. The second model used a stepwise 
backward selection process. Both models provided similar final results.  Logistic regression 
assumptions were checked and multicollinearity excluded. Linear relationship between 
continuous independent variables and the logit transformation of the dependent variable was 
verified by plotting the means vs. the β estimates in quintiles. If a linear relationship was not 
present then the variable was dichotomized at the inflexion point. 
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The primary outcome was a composite of hospitalization for heart failure (HHF) and 
all-cause death. Cox proportional hazard regression models were used to model long-term event 
rate both in univariable and multivariable analysis. Cox model’s assumptions were verified. An 
interaction term between the variable of interest (MRA) and time was tested within the Cox 
model. In the multivariable models, the covariates for adjustment were chosen from 
demographic (age and gender), clinical (body mass index [BMI], LVEF, European region, 
congestion signs and symptoms, coronary revascularization, hypertension history, diabetes, 
medication, and systolic blood pressure), and laboratory (eGFR determined by the CKD-EPI 
formula22 and hemoglobin). All parameters were previously found to be independently 
associated with the outcome of HF hospitalization or all-cause death in the BIOSTAT cohort. 
These variables were also used to create a propensity score (PS) from a logistic regression 
model. The PS and its Logit were also used for adjustment as covariate providing similar 
results23 (data not shown).   
European region was divided in Southern countries (Greece, Italy, Serbia, Slovenia, and 
France) vs. Northern countries (Netherlands, Sweden, Norway, Germany, Poland, and United 
Kingdom).  
The adjudication of events (heart failure hospitalizations) were done by the treating 
physician.  
All analyses were performed with SAS® software version 9.4 (SAS Institute Inc., Cary, 
N.C., USA). 
 
Results 
Characteristics of the studied population 
At baseline, MRAs were prescribed in 741 (56%) patients. Characteristics of the 
patients according to MRA prescription at baseline and changes in MRA prescription between 
baseline and 9 months are presented in Table 1. Patients with MRA prescription at baseline 
were younger, more often male, had higher BMI, higher potassium levels, lower SBP, lower 
NT-pro BNP, were more often from southern Europe, had worse NYHA class, had more often a 
cardiac device, more coronary interventions, were more often hospitalized for worsening HF in 
the year before the baseline visit, had ACEi/ARBs prescribed more frequently but achieved 
≥50% target dose of such therapies less frequently, had β-blockers prescribed more frequently 
but also achieved ≥50% target dose of β-blockers less frequently, they also had digoxin 
prescribed more frequently (p<0.05 for all). As compared to patients without any MRA 
prescription, patients in which an MRA was prescribed both at baseline and 9 months were 
younger, were more often from southern Europe (but Southern Europe patients were also the 
ones who had higher proportion of MRA discontinuation at some point between baseline and 9 
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months), had lower heart rate, lower SBP, higher serum potassium levels, had more often 
hypertension history, and a loop diuretic prescribed (p<0.05 for all) – Table 1. 
Characterization of patients with and without MRA at baseline 
At baseline, MRA recipients had greater odds of having higher BMI, being from 
Southern Europe, having worse NYHA class, had been hospitalized for worsening HF in the 
year before the baseline visit, have a device implanted, and hypertension history. Patients not 
receiving MRA therapy had higher odds of being older, have higher blood pressure, and 
hypokalaemia – Table 2.  
Factors associated with MRA therapy change up to 9 months during the post discharge 
period  
From the 1325 patients present at baseline, 276 (21%) were lost to follow-up, from 
which 169 (61%) died, and 107 (39%) patients did not complete the 9-month visit (data 
missing). Characteristics of these 276 compared with the remaining 1049 patients are depicted 
in Supplementary Table 1.  
Of the 1049 patients who completed both baseline and 9-month visit, an MRA was 
prescribed at baseline in 585 (56%) patients and at 9 months in 662 (63%) patients. Among the 
585 patients with an MRA prescription at baseline, 91 (16%) had discontinued therapy and 
among the 461 (44%) patients without MRA prescription at baseline, 168 (36%) had initiated 
therapy subsequently – Table 3 and Figure 2. When looking at the specific drug 448 (42.8%) of 
the patients were taking spironolactone and 137 (13.1%) eplerenone. The proportion of patients 
who discontinued spironolactone and eplerenone was similar (15% and 17.5%, respectively), 
whereas the majority of patients who initiated MRA during the 9-month follow-up were started 
on spironolactone (23.9% vs. 12.6%) – Supplementary Table 2.    
Factors associated with MRA discontinuation were a higher LVEF and worse NYHA 
class. Having a higher heart rate, SBP ≥140 mmHg and K+ <4 mmol/L at baseline was 
associated with MRA initiation between baseline and 9 months, whereas patients from Southern 
Europe were less likely to initiate an MRA between baseline and 9 months – Table 4. Of the 
1049 patients who completed the two visits, 578 (55%) had an echocardiography performed at 
both visits (45% missing values). Of these 578 patients, 199 (34.4%) had improved LVEF 
above 35%. Compared to patients who maintained a LVEF below 35%, subjects with LVEF 
improvement were less likely to maintain MRA during the 9-month follow-up (55.7% vs. 
37.2%, respectively) - Supplementary Table 3. 
Outcome associations 
MRA prescription both at baseline and 9 months was not associated with lower primary 
outcome event rates as compared to not having an MRA prescription (adjusted HR [95%CI] 
=1.02 [0.66-1.58], p =0.93). MRA prescribed only at baseline was associated with dismal 
outcomes in unadjusted models but not after adjustment (unadjusted HR [95%CI] =1.80 [1.07-
8 
 
3.05], p =0.028 and adjusted HF [95%CI] =1.68 [0.62-3.07], p =0.092).  MRA prescription only 
at 9 months was also not associated with the primary outcome of mortality or heart failure 
hospitalization (adjusted HR [95%CI] =1.50 [0.89-2.53], p =0.13) – Table 5. 
 
Discussion   
Our study based on a symptomatic HFrEF population with suboptimal ACEi/ARB 
and/or β-blocker therapy showed that MRAs were largely under-prescribed and frequently 
changed (i.e., discontinued or initiated) in a short follow-up of 9 months. In this population, 
only ≈56% of patients with HFrEF with a formal indication for MRA treatment were actually 
receiving a MRA and within 9 months more than 15% of patients receiving an MRA 
discontinued, while another 36% without MRA at baseline initiated. We identified common 
features and determinants for MRA prescription and discontinuation. To the best of our 
knowledge, this is the first report on treatment initiation and cessation in only 9 months’ time. It 
is, therefore, very difficult to categorize patients in observational studies in MRA vs. non-MRA, 
since receiving an MRA therapy is a highly unstable condition and moving target. 
Consequently, reports of observational data, emphasizing lack of association of MRA therapy 
with clinical benefit, are in contrast with the findings of multiple randomised clinical trials. 
These reports are usually fraught with residual biases but are also critically invalidated because 
all are based on the wrong assumption that patients prescribed MRA therapy at baseline keep 
their medications unchanged throughout the course of the observation periods17, 18.  
 Previous observational reports confirmed that MRAs are under-prescribed. In the “Get 
With The Guidelines-HF quality improvement registry”4, only about one-third of patients with a 
formal MRA indication (and no compelling contra-indication) had the corresponding 
prescription, that varied widely across United States (US) regions and clinicians. In that 
registry, MRA prescription was also less common among elderly patients, those who have 
worse renal function, and lower blood pressure. In our study patients with higher and improved 
LVEF and worse NYHA class were more likely to have MRAs discontinued between baseline 
and 9 months. Interestingly, patients with hypertension history more often received MRA 
therapy, whereas patients not receiving MRAs had more often SBP ≥140 mmHg and 
hypokalemia, which is consistent with the anti-hypertensive and potassium-sparing effects of 
MRA therapy24.  
More frequent use of MRA therapy in patients with highest BMIs suggests that 
clinicians may intuitively perceive that MRA therapy is more effective in overweight patients. 
Actually, experimental and clinical data suggest that this may be the case25. Interestingly, we 
have also recently reported data from the Eplerenone for Heart Failure with Mild Symptoms 
(EMPHASIS-HF) trial suggesting that patients with abdominal obesity derive the largest benefit 
from eplerenone therapy26, 27.  
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The EURObservational Research Programme: Heart Failure Pilot Survey (ESC-HF 
Pilot), enrolled 5118 patients admitted for acute HF from 136 cardiology centres in 12 European 
countries in 2009-2010. In this survey, the rate of MRA therapy at hospital discharge was ~25% 
prior to hospitalization and ~50% after hospitalization28. The use of MRAs in the US is even 
lower than in Europe29, 30. Our data suggest that MRA use in the periods between 2009-2010 did 
not improve much up to 2010-2012, with only about half of the patients with compelling 
indication actually receiving the drug. In the 2008 HF guidelines of the European Society of 
Cardiology (ESC) is stated that “aldosterone antagonists should be considered in all patients 
with a LVEF ≤35% and severely symptomatic HF”21, hence most patients included in our study 
had formal indication for MRAs. It should be noticed that the results of EMPHASIS-HF trial2 
expanding the recommendation of use of MRA therapy to all symptomatic HFrEF patients was 
only integrated in the 2012 ESC guidelines20 and subsequently in the 2016 ESC guidelines31.  
Despite guideline indication, other factors may be responsible for the persistently low 
prescription rate, and these include the excessive concern raised by the publication of 
population-based studies associating MRA therapy to the increase of hyperkalemia-associated 
morbidity and mortality32, 33. As subsequently recognised, patients enrolled in these studies 
commonly received inappropriate dosing, or had formal contra-indications to MRA therapy, and 
had below trial and guideline recommended serum potassium and renal function monitoring34-36. 
It is also noticeable that there is a poor understanding of the mechanisms of action of MRAs 
beyond their “diuretic with potassium sparing properties” heading37, lack of pharmaceutical 
company–sponsored drug marketing and education for clinicians4, and lack of guidance on how 
to initiate MRAs on a background of ACEi/ARBs and β-blockers up-titration13, 38. The 
educational gap must be recognized and specifically addressed. Spironolactone is a generic 
drug, orphan from any industry promotional or educational support. Eplerenone is hardly 
supported by its single sponsor because of quick loss of patent short after its market launch.  
 In our study, a high rate (more than 15%) of MRA discontinuation during a short period 
of follow-up (≈9months) was observed. However, an even higher rate of MRA initiation (in 
patients without baseline MRA prescription) was observed (36%), possibly reflecting the 
guidance to up-titrate HF therapies in the BIOSTAT program. Patients at the highest end of the 
guideline recommended HFrEF range (<35%) or with LVEF improvement above 35%, and with 
worse NYHA class were more likely to have MRA treatment discontinued. Moreover, being 
older was associated with having no MRA prescribed at all. Our data do not provide granularity 
on why patients have stopped the drug, but they may suggest that clinicians` perception of 
patients` status is likely to play a role in these decisions and are a potential target for 
intervention39. Patient compliance cannot be assessed from our data, and compliance with 
treatments is a major issue40, especially concerning MRAs41, 42. Notwithstanding, we may 
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observe that potassium levels were higher in the group of patients with MRA prescription, 
which is an indirect sign of treatment adherence.  
 
Clinical and Research Implications 
Our findings, together with other previous observations of under-use and under-dosing 
of MRA therapy should prompt a vigorous call to action. So many reports have consistently 
emphasised the lack of adherence with the highest evidence based strongly recommended life-
saving MRA therapy in HFrEF, with little proactive action taken, especially in Europe. At least 
in the US, the Get With The Guidelines initiative (GWTG) is aiming at mitigating the general 
issue of poor adherence to guidelines, with encouraging results5. Actions directed towards 
clinical education and training (not only in the field of Cardiology, but also Internal Medicine, 
Geriatrics, Emergency Medicine, Nephrology, Endocrinology, etc) should be applied in order to 
improve the use of MRA therapy, but also to instruct on how to make the best use of it. The 
main reason for under use, under dosing or frequent discontinuation and no re-initiation of 
MRAs is the excessive concern about the risk of worsening renal function and of hyperkalemia9, 
43-46. Although, it has been consistently reported that despite occasional decline in eGFR and rise 
in potassium after initiating or up titrating an MRA, patients do benefit from life-saving MRA 
therapy43. It also appears that in clinical practice, the rate of monitoring of renal function and 
serum potassium is suboptimal, and below guideline recommendation36. Therefore, emphasizing 
that both decline in eGFR and rise in potassium are predictable, frequently transient and 
reversible and also manageable is an important part of education about optimal guideline 
implementation and disease management programs. Regarding the new potassium binders7,40,4, 
rather than increasing the undue concern about hyperkalaemia as a consequence of marketing-
based medicine, we should encourage generating appropriate trials evidence that these may 
indeed improve the use of MRA therapy and consequently maximise clinical benefit. More 
frequent and guideline-based potassium and renal function monitoring should also be 
emphasized, given the very low rate of such monitoring associated with the use of MRA in daily 
practice47. Improvement in health-care systems and “HF programmes” such as nurse-led HF 
care, should be widely implemented since they increase adherence to therapy and improve 
outcomes while reducing overall costs48, 49,50. From a research perspective, the development of 
point of care home self-monitoring of serum potassium and renal function, together with other 
congestion assessments, backed by electronic algorithms, and other prescription-helping tools 
may improve quality care provision while monitoring performance measures. 
Future reports of observational data should take into account the prescription changes 
during the observation period, and these MRA prescription alterations should be included in the 
analysis in a time-dependent manner in order to mitigate treatment allocation bias and to 
provide a closer picture of “real-world” clinical practice. 
11 
 
 
Limitations 
Several limitations should be noticed in this study. First, this is a secondary analysis of a 
prospective non-randomized observational study, therefore all limitations inherent to such 
analysis are applied herein, including the inability to infer causality (for example, we cannot 
know if patients with worse NYHA class were more likely to have MRA discontinued because 
they were “sicker” or if they were more symptomatic because they did not have MRA 
prescribed). Second, this study was not designed to address MRA prescription with sufficient 
granularity, hence these data do not allow to assess treatment doses or MRA prescription before 
baseline visit nor the exact timing where the medication was stopped or initiated. Third, patient 
selection for the BIOSTAT-CHF study was based on under-prescription of ACEi and β-
blockers, therefore MRA under-prescription possibly does not reflect “real life” completely. On 
the other hand, the MRA prescription increase observed between visits may represent an over-
estimation of “real-world” practice, as doctors participating in the BIOSTAT program were 
clearly instructed to up-titrate HF treatments, hence limiting results generalizability and external 
validity. Third, the reason(s) why patients have discontinued MRAs are not depicted in the 
dataset. Medication registry was mandatory at each visit but the reason why a medication was 
discontinued was not registered. Therefore, we cannot know how many patients discontinued 
MRA due to hyperkalemia, worsening renal function or gynecomastia, for example. Lastly, 
association of MRA use with outcome is not possible to be determine due to high rates of 
discontinuation/initiation during follow up. This may be turned in to a strength of this 
manuscript, demonstrating that all “real-life” outcome associations (particularly with MRAs) 
are prone to this type of bias and are therefore potentially misleading.  
 
Conclusion 
In this multicenter international European cohort, MRAs were largely underprescribed 
and frequently discontinued. Only slightly more than half of the patients with indication for 
MRA therapy received it and more that 15% of patients discontinued therapy in the few months 
following the baseline visit, while other 36% of patients without MRA prescription at baseline 
initiated it, reflecting the “up-titration” guidance of the BIOSTAT program. We identified 
determinants of prescription and therapy discontinuation and we suggest actionable measures to 
improve prescription and adherence. Given the frequent dynamic changes in therapy, we 
strongly warn against the use of observational data to infer about association between MRA use 
at a certain time point and subsequent outcome. 
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Figure 1. Study and present analysis flow-chart 
Legend: HF, heart failure; MRA, mineralocorticoid receptor antagonist; LVEF, left ventricular 
ejection fraction; eGFR, estimated glomerular filtration rate. 
 
 
 
 
 
17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Percentage (%) of patients with MRAs prescribed in the two study visits relative to the 
total (n=1049) of the patients who completed the two study visits and changes in MRA 
prescription between baseline and 9 months 
Legend: MRA, mineralocorticoid receptor antagonist. 
Total=1046 patients due to 3 (0.3%) missing values. 
 
 Table 1. Characteristics of the BIOSTAT population 
  Baseline Changes between Baseline and 9 months 
Variables 
All  
(N=1325) 
No MRA 
(N=584) 
MRA 
 (N=741) 
p All (N=1049) 
MRA at both 
visits 
(N=494) 
MRA 
discontinuation  
(N=91) 
MRA  
initiation 
(N=168) 
No MRA 
(N=293) 
p for 
trend 
Age, years 66.1 ± 12.2 68.2 ± 12.2 64.4 ± 12.0 <0.001 65.4 ± 12.2 63.6 ± 11.9 65.7 ± 12.4 64.6 ± 12.4 68.9 ± 12.0 <0.001 
Male gender, n (%) 1027 (77.5) 433 (74.1) 594 (80.2) 0.009 811 (77.3) 393 (79.6) 71 (78.0) 130 (77.4) 215 (73.4) 0.25 
White caucasian, n (%) 1305 (98.5) 579 (99.1) 726 (98.0) 0.083 1035 (98.7) 484 (98.0) 91 (100.0) 166 (98.8) 291 (99.3) 0.26 
Southern Europe countries, n (%) 775 (58.5) 263 (45.0) 512 (69.1) <0.001 603 (57.5) 345 (69.8) 59 (64.8) 81 (48.2) 115 (39.2) <0.001 
BMI, kg/m² 27.7 ± 5.5 27.1 ± 5.0 28.1 ± 5.8 0.001 27.8 ± 5.4 28.4 ± 5.7 27.6 ± 6.2 28.4 ± 5.0 26.6 ± 4.8 <0.001 
Heart rate, bpm 83.2 ± 21.7 86.1 ± 24.3 81.0 ± 19.1 <0.001 83.5 ± 22.3 80.8 ± 18.9 83.8 ± 22.2 90.1 ± 25.3 84.3 ± 24.9 <0.001 
SBP, mmHg 123 ± 21 126 ± 23 120 ± 19 <0.001 123 ± 21 121 ± 19 121 ± 17 127 ± 23 127 ± 23 <0.001 
Pulmonary rales, n (%) 677 (52.4) 309 (54.7) 368 (50.5) 0.14 514 (50.1) 235 (48.2) 49 (54.4) 89 (54.3) 138 (49.3) 0.45 
Peripheral edema, n (%) 609 (56.9) 259 (58.1) 350 (56.0) 0.50 459 (54.4) 217 (52.5) 50 (62.5) 75 (58.6) 114 (52.1) 0.25 
Elevated JVP, n (%) 293 (31.7) 135 (35.2) 158 (29.2) 0.052 217 (29.3) 94 (25.0) 21 (34.4) 42 (35.9) 59 (32.1) 0.064 
NYHA class III/IV, n (%) 797 (61.4) 322 (56.8) 475 (65.1) 0.002 613 (59.6) 297 (60.7) 68 (75.6) 97 (59.9) 150 (52.6) 0.001 
Orthopnea, n (%) 439 (33.2) 184 (31.6) 255 (34.5) 0.27 327 (31.2) 148 (30.0) 38 (41.8) 66 (39.3) 74 (25.3) 0.002 
LVEF, % 26.2 ± 6.4 26.5 ± 6.3 26.0 ± 6.4 0.10 26.3 ± 6.2 25.9 ± 6.3 27.4 ± 5.4 26.1 ± 6.1 26.8 ± 6.2 0.078 
HHF within 12 months before baseline, n (%)  447 (33.7) 169 (28.9) 278 (37.5) 0.001 346 (31.6) 181 (35.0) 35 (36.1) 44 (25.3) 86 (27.9) 0.032 
Primary HF etiology, n (%) - - - 0.12 - - - -  0.12 
    Ischemic 574 (43.3) 242 (41.4) 332 (44.8) - 429 (40.9) 216 (43.7) 34 (37.4) 59 (35.1) 118 (40.3) - 
    Hypertensive 106 (8.0) 58 (9.9) 48 (6.5) - 82 (7.8) 30 (6.1) 10 (11.0) 12 (7.1) 30 (10.2) - 
    Valvular 73 (5.5) 33 (5.7) 40 (5.4) - 61 (5.8) 31 (6.3) 4 (4.4) 6 (3.6) 20 (6.8) - 
    Other/miscellaneous 572 (43.2) 251 (43.0) 321 (43.3) - 477 (45.5) 217 (43.9) 43 (47.3) 91 (54.2) 125 (42.7) - 
Hemoglobin, g/dL 13.5 ± 1.8 13.5 ± 1.8 13.5 ± 1.8 0.91 13.7 ± 1.8 13.4 ± 1.8 13.4 ± 1.8 13.8 ± 1.8 13.7 ± 1.8 0.252 
eGFR, ml/min/1.73m2 66.2 ± 20.7 65.5 ± 20.7 66.8 ± 20.6 0.23 67.7 ± 20.7 68.4 ± 20.4 66.9 ± 21.9 69.2 ± 20.0 65.8 ± 21.2 0.243 
eGFR <45 ml/min/1.73m2, n (%) 224 (16.9) 107 (18.3) 117 (15.8) 0.22 153 (14.6) 66 (13.4%) 14 (15.4) 19 (11.3) 53 (18.1) 0.17 
Sodium, mmol/L 139 ± 4 140 ± 4 139 ± 4 0.015 140 ± 4 139 ± 4 140 ± 4 140 ± 4 140 ± 4 0.020 
Potassium, mmol/L 4.2 ± 0.5 4.1 ± 0.4 4.2 ± 0.4 <0.001 4.2 ± 0.4 4.2 ± 0.4 4.1 ± 0.5 4.0 ± 0.4 4.2 ± 0.4 <0.001 
Potassium <4 mmol/L, n (%) 396 (29.9) 210 (36.0) 186 (25.1) <0.001 658 (62.7) 114 (23.1) 29 (31.9) 73 (43.5) 88 (30.0) <0.001 
LogNT-pro BNP, ng/L 2.97 ± 1.31 3.06 ± 1.34 2.90 ± 1.29 0.031 2.85 ± 1.26 2.74 ± 1.25 2.84 ± 1.23 3.00 ± 1.32 2.94 ± 1.24 0.072 
Hypertension, n (%) 756 (57.1) 317 (54.3) 439 (59.2) 0.070 603 (57.5) 301 (60.9) 59 (64.8) 91 (54.2) 152 (51.9) 0.030 
Atrial Fibrillation, n (%) 562 (42.4) 249 (42.6) 313 (42.2) 0.88 426 (40.6) 197 (39.9) 39 (42.9) 67 (39.9) 122 (41.6) 0.93 
Diabetes mellitus, n (%) 402 (30.3) 163 (27.9) 239 (32.3) 0.088 297 (28.3) 145 (29.4) 31 (34.1) 54 (32.1) 66 (22.5) 0.050 
COPD, n (%) 220 (16.6) 97 (16.6) 123 (16.6) 0.99 166 (15.8) 75 (15.2) 13 (14.3) 26 (15.5) 51 (17.4) 0.83 
Stroke, n (%) 119 (9.0) 50 (8.6) 69 (9.3) 0.64 86 (8.2) 43 (8.7) 5 (5.5) 10 (6.0) 27 (9.2) 0.46 
PAD, n (%) 123 (9.3) 47 (8.0) 76 (10.3) 0.17 88 (8.4) 46 (9.3) 8 (8.8) 15 (8.9) 19 (6.5) 0.57 
Device therapy, n (%) 336 (25.4) 116 (19.9) 220 (29.7) <0.001 255 (24.3) 137 (27.7) 27 (29.7) 32 (19.0) 59 (20.1) 0.020 
PCI or CABG, n (%) 411 (31.0) 156 (26.7) 255 (34.4) 0.003 306 (29.2) 165 (33.4) 23 (25.3) 42 (25.0) 74 (25.3) 0.036 
Loop diuretic, n (%) 1319 (99.5) 582 (99.7) 737 (99.5) 0.70** 1044 (99.5) 400 (81.0) 59 (64.8) 130 (77.4) 204 (69.6) <0.001 
ACEi/ARB, n (%) 995 (75.1) 421 (72.1) 574 (77.5) 0.025 800 (76.3) 458 (92.7) 79 (86.8) 153 (91.1) 264 (90.1) 0.26 
≥50% dose, n (%)* 681 (54.4) 328 (59.7) 353 (50.2) <0.001 586 (55.9) 263 (53.2) 45 (49.5) 106 (63.1) 270 (58.0) 0.071 
Beta-blocker, n (%) 1108 (83.6) 464 (79.5) 644 (86.9) <0.001 889 (84.7) 473 (95.7) 84 (92.3) 159 (94.6) 274 (93.5) 0.41 
≥50% dose, n (%)* 455 (36.3) 220 (40.1) 235 (33.4) 0.015 398 (37.9) 187 (37.9) 32 (35.2) 82 (48.8) 124 (42.3) 0.052 
Digoxin, n (%) 250 (18.9) 95 (16.3) 155 (20.9) 0.032 188 (17.9) 90 (18.2) 20 (22.0) 31 (18.5) 36 (12.3) 0.072 
*At V1 the up-titration period was the first 3 months. Patients who were lost to follow-up OR who died during the uptitration period were excluded from this analysis. For follow-up purposes only patients who completed the two visits 
were considered. 
** Fisher exact test. 
All variables have ≤10% missing values (except peripheral edema and jugular venous pressure, proportion of missing values are 19.2% and 30.3% respectively). 
Legend: MRA, mineralocorticoid receptor antagonist; SBP, systolic blood pressure; JVP, jugular venous pressure; NYHA, New York Heart Association; H, hospitalization; HF, heart failure; eGFR, estimated glomerular filtration rate; 
NT-pro BNP, n-terminal pro brain natriuretic peptide; COPD, chronic pulmonary obstructive disease; PAD, peripheral artery disease; PCI or CABG, percutaneous coronary intervention or coronary artery bypass grafting; ACEi/ARB, 
angiotensin converting enzyme inhibitor/angiotensin receptor blocker. 
Country location in the BIOSTAT-CHF were considered as follows: Southern Europe: Greece, Italy, France, Serbia, and Slovenia; Northern Europe: Netherlands, Sweden, Norway, Germany, Poland, and United Kingdom. 
  
 
Table 2. Logistic regression: factors associated with and without MRA prescription at visit 1 
Baseline 
Factors associated with MRA prescription Odds ratio (95% CI) p-value 
Southern Europe countries 2.39 (1.87-3.05) <0.001 
BMI (per 5 kg/m² increase) 1.14 (1.02-1.28) 0.025 
HHF in the 12 months before baseline visit 1.34 (1.04-1.73) 0.024 
NYHA class III/IV 1.47 (1.16-1.88) 0.002 
Device therapy 1.62 (1.22-2.15) 0.001 
Hypertension history 1.30 (1.01-1.68) 0.044 
Age (per 10 years increase) 0.79 (0.71-0.87) <0.001 
SBP ≥140 mmHg 0.55 (0.41-0.75) <0.001 
Potassium <4 mmol/l 0.59 (0.46-0.77) <0.001 
A backward conditional model was performed based on variables that have an association with a p-value <0.2 in Table 1 
retaining in the final model the variable with a p-value <0.05. 
Legend: MRA, mineralocorticoid receptor antagonist; BMI, body mass index; HHF, heart failure hospitalization; SBP, 
systolic blood pressure; NYHA, New York Heart Association; ACEi/ARB, angiotensin converting enzyme 
inhibitor/angiotensin receptor blocker. 
Country location in the BIOSTAT-CHF were considered as follows: Southern Europe: Greece, Italy, France, Serbia, and 
Slovenia; Northern Europe: Netherlands, Sweden, Norway, Germany, Poland, and United Kingdom. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 3. MRA prescription drop out and initiation from baseline to 9 months in the 1049 patients who 
completed the two visits 
MRA (yes/no) 
n (%) 
MRA at Baseline 
n=585 (55.9) 
No MRA at Baseline 
n=461 (44.1) 
p-value 
MRA at 9 months 
n=662 (63.3) 
494 (84.4) 168 (36.4) 
 
 
<0.001 
 
No MRA at 9 months 
n=384 (36.7) 
91 (15.6) 293 (63.6) 
Legend: MRA, mineralocorticoid receptor antagonist. 
The % presented are relative to the total of 1046 patients due to 3 (0.3%) missing values. 
 
  
Table 4. Multinomial regression factors associated with MRA prescription change from baseline to 9 
months (reference: MRA maintenance from baseline to 9 months) 
MRA discontinuation (MRA at baseline but not at 9 months) Odds Ratio (95%CI) p-value 
LVEF (per 5% increase) 1.27 (1.04-1.56) 0.020 
NYHA class III/IV 2.04 (1.20-3.48) 0.009 
PCI or CABG 0.58 (0.33-0.99) 0.047 
MRA initiation (no MRA at baseline but prescribed at 9 months) Odds Ratio (95%CI) p-value 
Heart rate (per 10 bpm increase) 1.16 (1.07-1.26) 0.001 
Potassium <4 mmol/L 2.47 (1.66-3.66) <0.001 
SBP ≥140 mmHg 1.82 (1.16-2.86) 0.010 
Southern Europe countries 0.52 (0.35-0.78) 0.001 
No MRA (no MRA at baseline neither at 9 months) Odds Ratio (95%CI) p-value 
Age (per 10 years increase) 1.37 (1.19-1.59) <0.001 
BMI (per 5 kg/m² increase) 0.78 (0.66-0.91) 0.002 
NYHA class III/IV 0.68 (0.49-0.95) 0.022 
Hypertension history 0.70 (0.49-1.00) 0.050 
A backward was performed according to the type 3 analyses effect (global effect).  
Legend: MRA, mineralocorticoid receptor antagonist; LVEF, left ventricular ejection fraction; BMI, body mass index; SBP, 
systolic blood pressure; NYHA, New York Heart Association. 
Country location in the BIOSTAT-CHF were considered as follows: Southern Europe: Greece, Italy, France, Serbia, and 
Slovenia; Northern Europe: Netherlands, Sweden, Norway, Germany, Poland, and United Kingdom. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Primary outcome associations for MRA therapy between V1 and V2  
 Unadjusted HR 
(95%CI) 
p-value Adjusted HR* 
(95%CI) 
p-value 
No MRA (reference) - 0.10 - 0.14 
MRA baseline+9 months (yes) 1.00 (0.69-1.46) 0.99 1.02 (0.66-1.58) 0.93 
MRA only baseline (yes) 1.80 (1.07-3.05) 0.028 1.68 (0.92-3.07) 0.092 
MRA only 9 months (yes) 1.24 (0.78-1.97) 0.36 1.50 (0.89-2.53) 0.13 
The 1049 patients who completed the two study visits were included in the analysis. Time was set from 9 months until the 
end of the study and events previous to 9 months were censored.  
*adjusted on the clinical model derived from the BIOSTAT dataset that includes age, heart failure hospitalization in the last 
year, peripheral edema, systolic blood pressure, estimated glomerular filtration rate, urea, NT-pro BNP, hemoglobin, sodium, 
and use of beta-blocking agent at baseline. 
Legend: MRA, mineralocorticoid receptor antagonist; HR, hazard ratio; CI, confidence interval. 
 
 
Figure 1. Study and present analysis flow-chart 
 
Legend: HF, heart failure; MRA, mineralocorticoid receptor antagonist; LVEF, left ventricular ejection fraction; 
eGFR, estimated glomerular filtration rate. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Percentage (%) of patients with MRAs prescribed in the two study visits relative to the 
total (n=1049) of the patients who completed the two study visits and changes in MRA 
prescription between baseline and 9 months 
 
Legend: MRA, mineralocorticoid receptor antagonist. 
Total=1046 patients due to 3 (0.3%) missing values. 
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Supplemental Material 
 
Supplemental Table 1. Comparison of the characteristics of the patients who died or who were 
lost to follow-up with the whole baseline population 
  
Baseline 
Dead or Lost to 
Follow-up 
P-value 
Variables (N=1325) (N=276)  
MRA at baseline, n (%) 741 (55.9) 154 (55.8) 0.962 
Age, years 66.1 ± 12.2 68.4 ± 11.9 <0.001 
Male gender, n (%) 1027 (77.5%) 216 (78.3) 0.737 
White caucasian, n (%) 1305 (98.5%) 270 (97.8) 0.309 
Southern Europe countries, n (%) 775 (58.5%) 172 (62.3) 0.147 
BMI, kg/m² 27.7 ± 5.5 27.1 ± 5.5 0.06 
Heart rate, bpm 83.2 ± 21.7 82.2 ± 19.0 0.38 
SBP, mmHg 123 ± 21 119 ± 27 0.002 
Pulmonary rales, n (%) 677 (52.4%) 163 (60.8) 0.002 
Peripheral edema, n (%) 609 (56.9%) 150 (65.8) 0.002 
Elevated JVP, n (%) 293 (31.7%) 76 (41.5) 0.001 
NYHA class III/IV, n (%) 797 (61.4%) 184 (68.7) 0.006 
Orthopnea, n (%) 439 (33.2%) 112 (40.6) 0.003 
LVEF, % 26.2 ± 6.4 25.8 ± 6.9 0.23 
Primary HF etiology, n (%) -  0.003 
    Ischemic 574 (43.3%) 145 (52.5)  
    Hypertensive 106 (8.0%) 24 (8.7)  
    Valvular 73 (5.5%) 12 (4.3)  
    Other/miscellaneous 572 (43.2%) 95 (34.4)  
Hemoglobin, g/dL 13.5 ± 1.8 12.9 ± 1.8 <0.001 
eGFR, ml/min/1.73m2 66.2 ± 20.7 60.8 ± 19.5 <0.001 
eGFR <45 ml/min/1.73m2, n (%) 224 (16.9%) 71 (25.7) <0.001 
Sodium, mmol/L 139 ± 4 138.6 ± 4.3 <0.001 
Potassium, mmol/L 4.2 ± 0.5 4.1 ± 0.5 <0.001 
Potassium <4 mmol/L, n (%) 396 (29.9%) 107 (38.8) 0.12 
LogNT-pro BNP, ng/L 2.97 ± 1.31 3.45 ± 1.41 <0.001 
Hypertension, n (%) 756 (57.1%) 153 (55.4) 0.541 
Atrial Fibrillation, n (%) 562 (42.4%) 136 (49.3) 0.010 
Diabetes mellitus, n (%) 402 (30.3%) 105 (38.0) 0.002 
COPD, n (%) 220 (16.6%) 54 (19.6) 0.137 
Stroke, n (%) 119 (9.0%) 33 (12.0) 0.052 
PAD, n (%) 123 (9.3%) 35 (12.7) 0.029 
Device therapy, n (%) 336 (25.4%) 81 (29.3) 0.087 
PCI or CABG, n (%) 411 (31.0%) 105 (38.0) 0.005 
Loop diuretic, n (%) 1319 (99.5%) 275 (99.6) 0.801 
ACEi/ARB, n (%) 995 (75.1%) 195 (70.7) 0.055 
≥50% dose, n (%)* 681 (54.4%) 121 (43.8) <0.001 
Beta-blocker, n (%) 1108 (83.6%) 219 (79.3) 0.031 
≥50% dose, n (%)* 455 (36.3%) 73 (26.4) <0.001 
Digoxin, n (%) 250 (18.9%) 62 (22.5) 0.086 
Deaths, n (%) 297 (22.4) 169 (61.2) <0.001 
*At V1 the up-titration period was the first 3 months. 
Legend: MRA, mineralocorticoid receptor antagonist; SBP, systolic blood pressure; JVP, jugular venous pressure; 
NYHA, New York Heart Association; HF, heart failure; eGFR, estimated glomerular filtration rate; NT-pro BNP, n-
terminal pro brain natriuretic peptide; COPD, chronic pulmonary obstructive disease; PAD, peripheral artery disease; 
PCI or CABG, percutaneous coronary intervention or coronary artery bypass grafting; ACEi/ARB, angiotensin 
converting enzyme inhibitor/angiotensin receptor blocker. 
Country location in the BIOSTAT-CHF were considered as follows: Southern Europe: Greece, Italy, France, Serbia, 
and Slovenia; Northern Europe: Netherlands, Sweden, Norway, Germany, Poland, and United Kingdom. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Supplemental Table 2. Spironolactone or Eplerenone prescription drop out and initiation from 
baseline to 9 months in the 1049 patients who completed the two visits 
 Spironolactone at 
Baseline 
n=448 (42.8) 
Eplerenone at 
Baseline 
n=137 (13.1) 
No MRA at 
Baseline 
n=461 (44.1) 
p-value 
Spironolactone at 9 
months 
n=480 (45.9) 
367 (81.9) 
 
3 (2.2) 110 (23.9) 
 
 
<0.001 
 
Eplerenone at 9 
months 
n=182 (17.4) 
14 (3.1) 
 
110 (80.3) 58 (12.6) 
No MRA at 9 
months 
n=384 (36.7) 
67 (15.0) 
 
24 (17.5) 293 (63.6) 
Legend: MRA, mineralocorticoid receptor antagonist. 
The % presented are relative to the total of 1046 patients due to 3 (0.3%) missing values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Supplemental Table 3. Patterns of MRA prescription relative to the proportion of patients who 
improved left ventricular ejection fraction above 35% from baseline to 9 months 
 
LVEF <35% 
(n=379) 
LVEF ≥35% 
(n=199) 
P-value 
MRA at both visits 211 (55.7%) 74 (37.2%)  
 
<0.001 
MRA only at baseline 21 (5.5%) 18 (9%) 
MRA only at 9 months 57 (15%) 31 (15.6%) 
No MRA 90 (23.7%) 76 (38.2%) 
Legend: LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist. 
From the 1049 patients who completed the 2 visits, 578 (55%) had an echo performed at both visits (45% missing 
values). 
